Covidien and PETNET Expand Access to Essential Radioisotopes Used in Nuclear Imaging

Covidien (St. Louis, MO, USA), a leading global provider of healthcare products, and PETNET Solutions (Hoffman Estates, IL, USA), a wholly-owned subsidiary of Siemens Medical Solutions USA, Inc. and a leader in radiopharmaceutical distribution, jointly announced they have entered into a joint marketing agreement to offer a combined range of high energy and low energy radioisotopes to the nuclear medicine community in the United States.

Through the agreement, Covidien Imaging Solutions and PETNET will create a network of nuclear imaging product offerings to expand customer access to a wider range of products, including molecular imaging agents (radiopharmaceuticals), designed to illuminate conditions, such as cancer or heart disease, during imaging procedures. The agreement brings together Covidien's single photon emission computed tomography (SPECT) products and PETNET's positron emission tomography (PET) products.

"This agreement further validates the efforts Covidien has undertaken in recent years to enhance our reputation as a valued supplier of essential diagnostic products," said Steve Hanley, president, Imaging Solutions, Covidien. "With the agreement we are positioned to offer our nuclear medicine customers expanded access to both product lines to help them provide better patient diagnostic services. It also provides PETNET with access to our extensive SPECT product offerings," Mr. Hanley added.

Moreover, this agreement allows both companies to offer customers enhanced service, expertise, and product sourcing options. "We are pleased to work in tandem with Covidien to offer radiopharmaceuticals for both PET and SPECT imaging. This agreement strengthens Siemens offerings in radiopharmaceutical distribution and contributes to the availability of molecular imaging to patients nationwide," stated Michael Reitermann, CEO, Siemens Medical Solutions, Molecular Imaging.

Covidien is a leading global healthcare products company that creates medical solutions for better patient outcomes. The company manufactures, distributes, and services a diverse range of industry-leading product lines in four segments: medical devices, imaging systems, pharmaceutical products, and medical supplies.

PETNET Solutions operates the largest PET radiopharmacy network with over 50 radiopharmacies and distribution centers worldwide to produce and distribute PET radiopharmaceuticals to hospitals, clinics, and research facilities for PET imaging. PETNET Solutions is currently growing its network of radiopharmacies to promote global PET utilization.

Related Links:
Covidien
PETNET Solutions